Indivior PLC (NASDAQ:INDV) Stock Position Raised by Toronto Dominion Bank

Toronto Dominion Bank raised its position in shares of Indivior PLC (NASDAQ:INDV) by 58.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,094,865 shares of the company’s stock after purchasing an additional 769,000 shares during the period. Toronto Dominion Bank owned 1.52% of Indivior worth $44,872,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Chilton Investment Co. Inc. purchased a new stake in shares of Indivior during the 4th quarter worth about $263,000. ADAR1 Capital Management LLC acquired a new position in shares of Indivior during the 4th quarter valued at about $368,000. Cannon Global Investment Management LLC acquired a new position in shares of Indivior during the 1st quarter valued at about $563,000. Forsta AP Fonden acquired a new position in shares of Indivior during the 1st quarter valued at about $641,000. Finally, Campbell & CO Investment Adviser LLC increased its holdings in shares of Indivior by 2.8% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock valued at $573,000 after acquiring an additional 1,037 shares during the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Performance

NASDAQ INDV traded down $0.30 during trading on Friday, hitting $12.79. The company’s stock had a trading volume of 1,487,420 shares, compared to its average volume of 232,962. The company has a quick ratio of 0.74, a current ratio of 0.92 and a debt-to-equity ratio of 23.50. The firm has a 50 day moving average price of $15.09 and a 200 day moving average price of $17.64. The firm has a market cap of $1.76 billion, a P/E ratio of 1,279.00 and a beta of 0.69. Indivior PLC has a 52 week low of $9.14 and a 52 week high of $24.11.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). The firm had revenue of $284.00 million for the quarter, compared to the consensus estimate of $300.00 million. Indivior had a net margin of 0.44% and a return on equity of 842.72%. Equities research analysts forecast that Indivior PLC will post 1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on INDV shares. Piper Sandler initiated coverage on Indivior in a report on Tuesday. They set an “overweight” rating and a $22.00 price objective on the stock. Craig Hallum dropped their price target on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.